John Gever is a Freelance Writer at various publications, including Knowledia, MedPage Today, and MSN. He specializes in themes related to medicine and healthcare, focusing on topics such as immunology, rheumatology, oncology, and healthcare technology. His work frequently addresses health and wellness, alternative medicine, and advancements in digital health.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
John Gever's coverage primarily focuses on medical research related to autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. He heavily relies on data in his articles. Given the nature of his work, he would likely be interested in hearing from experts who can provide insights into new research findings or clinical data related to autoimmune diseases and their treatment.
As a journalist covering scientific and healthcare topics with a strong emphasis on citing data, John may prefer sources who are actively involved in medical research or have access to significant clinical data that can support the points being made. Additionally, given the technical nature of his reporting, pitches should be tailored towards providing detailed scientific insights rather than general healthcare trends.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Gever
No increase in disease worsening versus usual dosing, but questions remain
— Real-world study from Italy suggests the vasculitis drug works just fine Key Takeaways
— Noninvasive and nonradiological, this new technology may outperform Rodnan scoring Key Takeaways
By: John Gever
New study bolsters recommendations to base initial treatment on clinical response
By: John Gever
Opioids and gabapentin double the risks for OUD and overdose versus nondrug therapies
Most patients with rheumatoid arthritis (RA) whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission
Patients with acute low back pain (LBP) who got opioids or gabapentinoids as initial therapy faced twice the risk of opioid use disorder (OUD) or
Pivotal studies, now published, yield mixed results; new phase III trial now underway
Findings from a pair of randomized trials in Sjögren's disease with the anti-B cell biologic ianalumab have now been published and it's no longer clear that they're sufficient to support regulatory approvals.
No better than sham shots, and including steroids may worsen long-term outcomes
